Warren Stone Sells 22,128 Shares of NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. (NASDAQ:NEO) COO Warren Stone sold 22,128 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total transaction of $276,600.00. Following the transaction, the chief operating officer directly owned 121,631 shares of the company’s stock, valued at $1,520,387.50. The trade was a 15.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

NeoGenomics Stock Performance

NASDAQ:NEO opened at $12.97 on Friday. The firm has a market capitalization of $1.68 billion, a PE ratio of -14.74 and a beta of 1.58. The company has a quick ratio of 3.62, a current ratio of 3.91 and a debt-to-equity ratio of 0.41. NeoGenomics, Inc. has a 12-month low of $4.72 and a 12-month high of $15.32. The firm has a 50-day moving average price of $12.04 and a 200 day moving average price of $9.39.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The company had revenue of $187.80 million for the quarter, compared to the consensus estimate of $183.85 million. During the same period in the previous year, the business earned $0.05 earnings per share. The company’s quarterly revenue was up 12.0% on a year-over-year basis. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Research analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

NEO has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. Zacks Research raised shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 12th. TD Cowen restated a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of NeoGenomics in a research note on Monday, January 12th. Finally, Leerink Partners set a $14.00 price objective on shares of NeoGenomics in a report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, NeoGenomics has an average rating of “Hold” and an average target price of $12.00.

Hedge Funds Weigh In On NeoGenomics

A number of institutional investors have recently modified their holdings of the stock. First Light Asset Management LLC grew its stake in shares of NeoGenomics by 45.0% during the third quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock valued at $76,639,000 after purchasing an additional 3,080,837 shares during the last quarter. Greenhouse Funds LLLP lifted its holdings in NeoGenomics by 57.8% during the 2nd quarter. Greenhouse Funds LLLP now owns 7,431,147 shares of the medical research company’s stock worth $54,322,000 after buying an additional 2,722,823 shares in the last quarter. American Capital Management Inc. boosted its position in NeoGenomics by 120.9% in the 3rd quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock valued at $18,105,000 after buying an additional 1,283,390 shares during the last quarter. Aberdeen Group plc increased its stake in shares of NeoGenomics by 127.1% in the 4th quarter. Aberdeen Group plc now owns 1,798,939 shares of the medical research company’s stock valued at $21,156,000 after buying an additional 1,006,676 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of NeoGenomics in the 2nd quarter valued at $6,071,000. 98.50% of the stock is owned by institutional investors.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.